Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Anne Marie Kirsten

S51 Efficacy of Aclidinium Bromide Compared With Tiotropium and Placebo in Patients With Moderate to Severe COPD: A Phase IIIb Study: Abstract S51 Table 1

Thorax

Pulmonary

Respiratory Medicine

2012

English

Related publications

Cost-Effectiveness of Aclidinium Bromide Compared With Tiotropium Bromide From the Perspective of Copd Patient Populations

International Journal of Medicine and Pharmacy

2014

English

Effect of Aclidinium Bromide on Cough and Sputum Symptoms in Moderate-To-Severe COPD in Three Phase III Trials

BMJ Open Respiratory Research

Pulmonary

Respiratory Medicine

2016

English

Cost Versus Utility of Aclidinium Bromide 400 Μg Plus Formoterol Fumarate Dihydrate 12 Μg Compared to Aclidinium Bromide 400 Μg Alone in the Management of Moderate-To-Severe COPD

ClinicoEconomics and Outcomes Research

English

Overall and Cardiovascular Safety of Aclidinium Bromide in Patients With COPD: A Pooled Analysis of Six Phase III, Placebo-Controlled, Randomized Studies

Chronic Obstructive Pulmonary Diseases

Pulmonary

Respiratory Medicine

2016

English

Efficacy and Safety of Once-Daily QVA149 Compared With the Free Combination of Once-Daily Tiotropium Plus Twice-Daily Formoterol in Patients With Moderate-To-Severe COPD (QUANTIFY): A Randomised, Non-Inferiority Study

English

Efficacy and Safety of Fixed-Dose Combinations of Aclidinium Bromide/Formoterol Fumarate: The 24-Week, Randomized, Placebo-Controlled AUGMENT COPD Study

English

Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-To-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study

Arthritis and Rheumatology

English

Pss43 - Dupilumab Improves Absenteeism in Moderate-To-Severe Atopic Dermatitis Patients Compared With Placebo in Phase 3 Liberty Ad Solo Studies

English

Safety and Efficacy of Guselkumab in Japanese Patients With Moderate-To-Severe Plaque Psoriasis: A Randomised, Placebo-Controlled, Ascending Dose Study

British Journal of Dermatology

Dermatology

Medicine

2018

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Anne Marie Kirsten

S51 Efficacy of Aclidinium Bromide Compared With Tiotropium and Placebo in Patients With Moderate to Severe COPD: A Phase IIIb Study: Abstract S51 Table 1

Related publications

Cost-Effectiveness of Aclidinium Bromide Compared With Tiotropium Bromide From the Perspective of Copd Patient Populations

Effect of Aclidinium Bromide on Cough and Sputum Symptoms in Moderate-To-Severe COPD in Three Phase III Trials

Cost Versus Utility of Aclidinium Bromide 400 &Mu;g Plus Formoterol Fumarate Dihydrate 12 &Mu;g Compared to Aclidinium Bromide 400 &Mu;g Alone in the Management of Moderate-To-Severe COPD

Overall and Cardiovascular Safety of Aclidinium Bromide in Patients With COPD: A Pooled Analysis of Six Phase III, Placebo-Controlled, Randomized Studies

Efficacy and Safety of Once-Daily QVA149 Compared With the Free Combination of Once-Daily Tiotropium Plus Twice-Daily Formoterol in Patients With Moderate-To-Severe COPD (QUANTIFY): A Randomised, Non-Inferiority Study

Efficacy and Safety of Fixed-Dose Combinations of Aclidinium Bromide/Formoterol Fumarate: The 24-Week, Randomized, Placebo-Controlled AUGMENT COPD Study

Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-To-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study

Pss43 - Dupilumab Improves Absenteeism in Moderate-To-Severe Atopic Dermatitis Patients Compared With Placebo in Phase 3 Liberty Ad Solo Studies

Safety and Efficacy of Guselkumab in Japanese Patients With Moderate-To-Severe Plaque Psoriasis: A Randomised, Placebo-Controlled, Ascending Dose Study

Cost Versus Utility of Aclidinium Bromide 400 Μg Plus Formoterol Fumarate Dihydrate 12 Μg Compared to Aclidinium Bromide 400 Μg Alone in the Management of Moderate-To-Severe COPD